US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
NZ524806A
(en)
|
2000-10-23 |
2006-03-31 |
Smithkline Beecham Corp |
Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
|
KR20060111716A
(ko)
|
2002-01-22 |
2006-10-27 |
워너-램버트 캄파니 엘엘씨 |
2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
|
RU2004133811A
(ru)
|
2002-04-19 |
2005-04-20 |
Смитклайн Бичам Корпорейшн (US) |
Новые соединения
|
DE60335635D1
(de)
|
2002-05-22 |
2011-02-17 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
MXPA05001456A
(es)
|
2002-08-08 |
2005-06-06 |
Amgen Inc |
Ligandos del receptor vanilloide y su uso en tratamientos.
|
EP1648889B1
(en)
*
|
2003-07-11 |
2008-10-29 |
Warner-Lambert Company LLC |
Isethionate salt of a selective cdk4 inhibitor
|
ATE556056T1
(de)
|
2003-07-29 |
2012-05-15 |
Xenon Pharmaceuticals Inc |
Pyridylderivate und deren verwendung als therapeutische mittel
|
ES2375134T3
(es)
|
2003-07-30 |
2012-02-27 |
Xenon Pharmaceuticals Inc. |
Derivados de piperazina y su uso como agentes terapéuticos.
|
DK1663242T3
(da)
*
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
WO2005033105A2
(en)
|
2003-09-30 |
2005-04-14 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US7534798B2
(en)
|
2004-02-11 |
2009-05-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
EP1740184A1
(en)
*
|
2004-03-30 |
2007-01-10 |
Pfizer Products Incorporated |
Combinations of signal transduction inhibitors
|
ATE485824T1
(de)
*
|
2004-04-13 |
2010-11-15 |
Icagen Inc |
Polycyclische pyrimidine als kaliumionenkanal- modulatoren
|
AU2005284904A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
WO2006034441A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
WO2006034440A2
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
JP5094398B2
(ja)
|
2004-09-20 |
2012-12-12 |
ゼノン・ファーマシューティカルズ・インコーポレイテッド |
複素環式誘導体およびステアロイル−CoAデサチュラーゼのメディエータとしてのそれらの使用
|
MX2007003318A
(es)
|
2004-09-20 |
2007-05-18 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como agentes terapeuticos.
|
CA2580857A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
WO2006034341A2
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
TW200626138A
(en)
|
2004-09-20 |
2006-08-01 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents
|
US7314933B2
(en)
|
2004-10-22 |
2008-01-01 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CA2577588C
(en)
|
2004-10-29 |
2013-09-10 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting bicyclic pyrimidine derivatives
|
US7947695B2
(en)
|
2005-01-14 |
2011-05-24 |
Janssen Pharmaceutica Nv |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
DE602006014502D1
(de)
|
2005-01-14 |
2010-07-08 |
Janssen Pharmaceutica Nv |
Pyrazolopyrimidine als zellzyklus-kinasehemmer
|
WO2006089311A1
(en)
|
2005-02-15 |
2006-08-24 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
JP2008535822A
(ja)
*
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
WO2006104917A2
(en)
*
|
2005-03-25 |
2006-10-05 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
DK2004641T3
(da)
|
2006-03-30 |
2011-01-24 |
Tibotec Pharm Ltd |
HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
AR060635A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
|
WO2007125405A2
(en)
*
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
EP2441757A1
(en)
*
|
2006-07-31 |
2012-04-18 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
WO2008016675A1
(en)
|
2006-08-01 |
2008-02-07 |
Praecis Pharmaceuticals Incorporated |
P38 kinase inhibitors
|
EP2078016B1
(en)
|
2006-10-19 |
2012-02-01 |
Signal Pharmaceuticals LLC |
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
|
US20100298557A1
(en)
*
|
2006-12-28 |
2010-11-25 |
Taisho Pharmaceutical Co., Ltd |
Pyrazolopyrimidine compound
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
JP2010525047A
(ja)
*
|
2007-04-27 |
2010-07-22 |
アストラゼネカ アクチボラグ |
増殖状態の処置のためのEphB4キナーゼ阻害剤としてのN’−(フェニル)−N−(モルホリン−4−イル−ピリジン−2−イル)−ピリミジン−2,4−ジアミン誘導体
|
CA2685588A1
(en)
|
2007-06-08 |
2008-12-11 |
Bayer Cropscience Sa |
Fungicide heterocyclyl-pyrimidinyl-amino derivatives
|
WO2009071535A1
(en)
*
|
2007-12-03 |
2009-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
CN101945867A
(zh)
|
2007-12-19 |
2011-01-12 |
安姆根有限公司 |
作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
KR20110017431A
(ko)
|
2008-06-10 |
2011-02-21 |
아보트 러보러터리즈 |
신규한 트리사이클릭 화합물
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
KR101353857B1
(ko)
*
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Cdk 억제제로서 피롤로피리미딘 화합물
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
CN102227409B
(zh)
*
|
2008-11-28 |
2014-03-26 |
兴和株式会社 |
吡啶-3-甲酰胺衍生物
|
MA32968B1
(fr)
|
2008-12-29 |
2012-01-02 |
Fovea Pharmaceuticals |
Composes quinazoline substitues
|
CA2751517A1
(en)
|
2009-02-13 |
2010-08-19 |
Fovea Pharmaceuticals |
[1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
|
AU2010232727A1
(en)
|
2009-03-31 |
2011-10-20 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
ES2561216T3
(es)
|
2009-05-13 |
2016-02-25 |
The University Of North Carolina At Chapel Hill |
Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
|
EP2440051A4
(en)
*
|
2009-06-08 |
2012-12-19 |
California Capital Equity Llc |
TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
|
CN102458402B
(zh)
|
2009-06-12 |
2013-10-02 |
百时美施贵宝公司 |
用作激酶调节剂的烟酰胺化合物
|
EP3091021B1
(en)
|
2009-10-26 |
2019-08-28 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
CR20170159A
(es)
|
2009-12-01 |
2017-06-26 |
Abbvie Inc |
Nuevos compuestos tricíclicos
|
SG181147A1
(en)
|
2009-12-01 |
2012-07-30 |
Abbott Lab |
Novel tricyclic compounds
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
WO2011156698A2
(en)
|
2010-06-11 |
2011-12-15 |
Abbott Laboratories |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
|
TW201204723A
(en)
|
2010-06-22 |
2012-02-01 |
Fovea Pharmaceuticals |
Heterocyclic compounds, their preparation and their therapeutic application
|
EP3567042B1
(en)
|
2010-10-25 |
2021-07-07 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
CA2818046A1
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
BR112013013790A2
(pt)
|
2010-12-17 |
2016-09-13 |
Hoffmann La Roche |
compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
DK2937349T3
(en)
|
2011-03-23 |
2017-02-20 |
Amgen Inc |
CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
|
CN105001165B
(zh)
|
2011-04-22 |
2020-06-23 |
西格诺药品有限公司 |
取代的二氨基嘧啶其组合物,和用其治疗的方法
|
TWI629983B
(zh)
|
2011-10-19 |
2018-07-21 |
標誌製藥公司 |
以tor激酶抑制劑治療癌症
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
PE20141696A1
(es)
|
2011-12-02 |
2014-11-08 |
Signal Pharm Llc |
Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il) piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b] pirazin-2(1h)-ona, una forma solida del mismo y metodos de su uso
|
JP6096219B2
(ja)
|
2012-01-13 |
2017-03-15 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物
|
CN104159896B
(zh)
*
|
2012-01-13 |
2017-05-24 |
百时美施贵宝公司 |
用作激酶抑制剂的杂环取代的吡啶基化合物
|
ES2630705T3
(es)
*
|
2012-01-13 |
2017-08-23 |
Bristol-Myers Squibb Company |
Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas
|
AU2013202305B2
(en)
|
2012-02-24 |
2015-03-12 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
WO2013170671A1
(zh)
*
|
2012-05-14 |
2013-11-21 |
华东理工大学 |
蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
SG11201408238WA
(en)
|
2012-06-13 |
2015-01-29 |
Incyte Corp |
Substituted tricyclic compounds as fgfr inhibitors
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
US9493454B2
(en)
|
2012-09-26 |
2016-11-15 |
Tolero Pharmaceuticals, Inc. |
Multiple kinase pathway inhibitors
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
JP6215338B2
(ja)
*
|
2012-11-08 |
2017-10-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
|
WO2014074675A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyridyl compounds useful as kinase modulators
|
WO2014089913A1
(zh)
*
|
2012-12-12 |
2014-06-19 |
山东亨利医药科技有限责任公司 |
作为酪氨酸激酶抑制剂的并环化合物
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
CN105188704B
(zh)
|
2013-01-16 |
2017-09-19 |
西格诺药品有限公司 |
被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
CN108434149B
(zh)
|
2013-03-15 |
2021-05-28 |
G1治疗公司 |
针对Rb阳性异常细胞增殖的HSPC节制性治疗
|
WO2014139145A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Hutchison Medipharma Limited |
Novel pyrimidine and pyridine compounds and usage thereof
|
US9782427B2
(en)
|
2013-04-17 |
2017-10-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
KR102221005B1
(ko)
|
2013-04-17 |
2021-02-26 |
시그날 파마소티칼 엘엘씨 |
전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
|
KR102271344B1
(ko)
|
2013-04-17 |
2021-07-01 |
시그날 파마소티칼 엘엘씨 |
디하이드로피라지노-피라진을 사용한 암의 치료
|
TWI654979B
(zh)
|
2013-04-17 |
2019-04-01 |
美商標誌製藥公司 |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
TWI656875B
(zh)
|
2013-04-17 |
2019-04-21 |
美商標誌製藥公司 |
藉二氫吡并吡治療癌症
|
WO2014172423A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
CN107474051B
(zh)
|
2013-05-29 |
2020-10-30 |
西格诺药品有限公司 |
二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
|
ES2812605T3
(es)
|
2013-12-20 |
2021-03-17 |
Signal Pharm Llc |
Compuestos de diaminopirimidilo sustituidos, composiciones de los mismos y procedimientos de tratamiento con ellos
|
AR098991A1
(es)
|
2014-01-03 |
2016-06-22 |
Bristol Myers Squibb Co |
Compuestos de nicotinamida sustituida con heteroarilo
|
JP2017504628A
(ja)
*
|
2014-01-31 |
2017-02-09 |
小野薬品工業株式会社 |
縮合イミダゾール化合物
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
LT3122359T
(lt)
|
2014-03-26 |
2021-03-25 |
Astex Therapeutics Ltd. |
Fgfr inhibitoriaus ir igf1r inhibitoriaus deriniai
|
SI3122358T1
(sl)
|
2014-03-26 |
2021-04-30 |
Astex Therapeutics Ltd. |
Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
|
WO2015160868A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
WO2015160882A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015161288A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
JP2017520603A
(ja)
|
2014-07-14 |
2017-07-27 |
シグナル ファーマシューティカルズ,エルエルシー |
置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
|
AU2015296322B2
(en)
|
2014-07-26 |
2019-09-19 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
CN104496983B
(zh)
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
CR20170390A
(es)
|
2015-02-20 |
2017-10-23 |
Incyte Holdings Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
CN110078741B
(zh)
*
|
2015-04-24 |
2021-10-01 |
广州再极医药科技有限公司 |
稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
CN107849039B
(zh)
|
2015-06-24 |
2020-07-03 |
百时美施贵宝公司 |
经杂芳基取代的氨基吡啶化合物
|
JP6720225B2
(ja)
|
2015-06-24 |
2020-07-08 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ヘテロアリール置換のアミノピリジン化合物
|
JP6720355B2
(ja)
|
2015-06-24 |
2020-07-08 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ヘテロアリール置換のアミノピリジン化合物
|
WO2017019487A1
(en)
|
2015-07-24 |
2017-02-02 |
Celgene Corporation |
Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
|
RU2747644C2
(ru)
|
2015-09-23 |
2021-05-11 |
Янссен Фармацевтика Нв |
Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака
|
EP3353177B1
(en)
|
2015-09-23 |
2020-06-03 |
Janssen Pharmaceutica NV |
Tricyclic heterocycles for the treatment of cancer
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
EP3362455A1
(en)
|
2015-10-16 |
2018-08-22 |
AbbVie Inc. |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
AU2017290748A1
(en)
*
|
2016-07-01 |
2019-01-17 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
BR112018077155A2
(pt)
*
|
2016-07-01 |
2019-04-02 |
G1 Therapeutics, Inc. |
processo para preparar um composto, e, composto
|
PT3546456T
(pt)
*
|
2016-11-28 |
2022-02-28 |
Teijin Pharma Ltd |
Cristal de derivado da pirido[3,4-d]pirimidina ou seu solvato
|
TWI823845B
(zh)
|
2017-01-06 |
2023-12-01 |
美商G1治療公司 |
用於治療癌症的組合療法
|
PE20191817A1
(es)
|
2017-05-11 |
2019-12-27 |
Bristol Myers Squibb Co |
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
SG11201912403SA
(en)
|
2017-06-22 |
2020-01-30 |
Celgene Corp |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
NZ759691A
(en)
|
2017-06-29 |
2023-05-26 |
G1 Therapeutics Inc |
Morphic forms of git38 and methods of manufacture thereof
|
CN107759596A
(zh)
*
|
2017-12-05 |
2018-03-06 |
安庆奇创药业有限公司 |
一种合成帕博西尼的方法
|
CN108299312B
(zh)
*
|
2018-03-29 |
2020-10-30 |
郑州大学第一附属医院 |
一组嘧啶类衍生物及其在制备抗肿瘤药物中的应用
|
SG11202010636VA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
WO2019213506A1
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
WO2020041770A1
(en)
|
2018-08-24 |
2020-02-27 |
G1 Therapeutics, Inc. |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US20230027026A1
(en)
*
|
2019-09-27 |
2023-01-26 |
Jubilant Biosys Limited |
Fused pyrimidine compounds, compositions and medicinal applications thereof
|
CR20220169A
(es)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de fgfr
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
JP2023505258A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式複素環
|
CA3162010A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CN115551856A
(zh)
*
|
2020-02-28 |
2022-12-30 |
重庆复尚源创医药技术有限公司 |
作为cdk2/4/6抑制剂的化合物
|
WO2021219731A2
(en)
*
|
2020-04-28 |
2021-11-04 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and uses thereof
|
IL298294A
(en)
|
2020-05-19 |
2023-01-01 |
G1 Therapeutics Inc |
Cyclin-dependent kinase inhibitory compounds for the treatment of medical disorders
|
CN113801139A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
|
CN113801118A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的蝶啶酮衍生物及其应用
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
CN113087708A
(zh)
*
|
2021-04-06 |
2021-07-09 |
南方医科大学 |
一种蝶啶酮类化合物及其应用
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
TW202328096A
(zh)
|
2021-08-27 |
2023-07-16 |
南韓商柳韓洋行 |
作為egfr抑制劑之含五員雜芳基之胺基吡啶化合物
|
TW202317106A
(zh)
*
|
2021-08-27 |
2023-05-01 |
南韓商柳韓洋行 |
作為egfr抑制劑之取代胺基吡啶化合物
|
WO2023143135A1
(zh)
*
|
2022-01-28 |
2023-08-03 |
赛诺哈勃药业(成都)有限公司 |
一种喹唑啉衍生物及其用途
|
WO2024020380A1
(en)
*
|
2022-07-18 |
2024-01-25 |
Iambic Therapeutics, Inc. |
Quinazoline compounds and methods of use
|